Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma

International Journal of Surgical Pathology

Volumn 13, Issue 2, 2005, Pages 135-142

  Raspollini, Maria Rosaria ^a   Castiglione, Francesca ^a   Garbini, Francesca ^a   Villanucci, Alessandro ^a   Amunni, Gianni ^a   Baroni, Gianna ^a   Boddi, Vieri ^a   Taddei, Gian Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chemotherapy; EGFR; MVD; Ovarian carcinoma; VEGF

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18144379214     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690501300202     Document Type: Article

References (26)

1. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Ann Rev Biochem 56:881-914, 1987
2. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99:538-548, 2002
3. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61: 5090-5101, 2001
4. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patiens with ovarian carcinoma. Cancer 95(4):808-815, 2002
5. O-Charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. C-erbB receptors in squamous cell carcinoma of the head and neck: Clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38:73-80, 2002
6. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
7. De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles and practice of oncology. 5th ed., Philadelphia, New York, Lippincott-Raven, pp. 333-347, 1997
8. TNM Classification of malignant tumours: UICC, 60th ed. Sobin LH and Wittekind Ch (eds). Geneva, Switzerland, 2002
9. Ali-Fermi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98:1423-1429, 2003
10. Aoki T, Nagakawa Y, Tsuchida A, Kasuya K, Kitamura K, Inoue K, Ozawa T, Koyanagi Y, Itoi T. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors: Oncol Rep 9: 761-765, 2002
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
12. Bosari S, Lee AK, DeLellis RA, Wiley B, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23: 755-761, 1992
13. Obermair A, Waisicky R, Kaider A, Preyer O, Losch A, Leodolter S, Kolbl H. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 138:175-182, 1999
14. Kaplan EL, Meier P. Nonparametric estimationfrom incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 34:187-202, 1972
16. De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles and practice of oncology. 5th ed. Philadelphia, New York, Lippincott-Raven. pp. 333-347, 1997
17. Mendelson J, Baselga J. Status of epidermal growth factor-receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799, 2003
18. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909-916, 1999
19. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4:2957-2966, 1998
20. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
21. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhanced the effects of the anti-epidermal growth factor-receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-4884, 2000
22. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
23. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206, 2001
24. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 19:67-73, 2000
25. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
26. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer 86:456-462, 2002